[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339276-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339276-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","guidelines-for-the-diagnosis-and-treatment-of-cutaneous-squamous-cell-carcinoma-a-grade-approach-for-evidence-evaluation-and-recommendations","Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma - a GRADE approach for evidence evaluation and recommendations","","Cutaneous squamous cell carcinoma (CSCC) is a substantial fraction of skin tumors, yet incidence can be difficult to estimate due to limited statistics and frequent overlap with mucosal forms. Although most cases have a favorable prognosis, locally advanced or metastatic disease occurs, particularly in immunocompromised individuals, solid-organ transplant recipients, and patients facing social difficulties. These guidelines from the Italian Association of Medical Oncologists use the GRADE framework to support evidence evaluation and clinical recommendations, covering diagnosis, treatment, and monitoring from early to advanced stages, including modern immunotherapies such as cemiplimab and pembrolizumab.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/guidelines-for-the-diagnosis-and-treatment-of-cutaneous-squamous-cell-carcinoma-a-grade-approach-for-evidence-evaluation-and-recommendations/339276/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/guidelines-for-the-diagnosis-and-treatment-of-cutaneous-squamous-cell-carcinoma-a-grade-approach-for-evidence-evaluation-and-recommendations/339276.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is cutaneous squamous cell carcinoma (CSCC) and how common is it?","Question",{"text":63,"@type":64},"CSCC accounts for about 20%–25% of all skin tumors. Precise incidence is often hard to determine due to limited statistics and its frequent inclusion with mucosal forms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who is at higher risk of locally advanced or metastatic CSCC?",{"text":68,"@type":64},"Patients who are immunocompromised, solid organ transplant recipients, or those facing social difficulties are more likely to develop locally advanced or metastatic disease.",{"name":70,"@type":61,"acceptedAnswer":71},"What approach do the guidelines use to evaluate evidence and make recommendations?",{"text":72,"@type":64},"The Italian Association of Medical Oncologists (AIOM) developed the guidelines using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339276,1790532728,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":108},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","REVIEW  \nGuidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology  \nP. Queirolo1, M. Cinquini2, G. Argenziano3, F. Bassetto4, P. Bossi5, A. Boutros6, C. Clemente7, V. de Giorgi8 , 9,  \nM. Del Vecchio10, R. Patuzzo11, E. Pennachioli1, K. Peris12, 13, P. Quaglino14, A. Reali15, I. Zalaudek16 & F. Spagnolo17 , 18􀀁 1Division of Melanoma, Sarcomas and Rare Tumors, IRCCS European Institute of Oncology, Milan; 2Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan; 3Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples; 4Clinic of Plastic Surgery, Department of Neuroscience, Padua University Hospital, Padua; 5IRCCS Humanitas Research Hospital, Milan; 6Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa; 7Surgical Pathology Department, IRCCS Galeazzi Sant’Ambrogio, Milan; 8Dermatology Unit, Azienda USL Toscana Centro, Florence; 9Section of Dermatology, Department of Health Sciences, University of Florence, Florence; 10Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 11Fondazione IRCCS Istituto Nazionale Dei Tumori, Melanoma and Sarcoma Unit, Milan; 12Dermatology, Department of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, Rome; 13Dermatology, Department of Medical and Surgery Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 14Department of Medical Sciences, Clinic of Dermatology, University of Turin, Turin; 15Radiation Oncology Department, Michele e Pietro Ferrero Hospital, Verduno; 16Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste; 17Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova; 18Department of Surgical Sciences and Integrated Diagnostics (DISC), Plastic Surgery Division, University of Genova, Genoa, Italy  \nAvailable online xxx  \nCutaneous squamous cell carcinoma (CSCC) accounts for w20%-25% of all skin tumors. Its precise incidence is often challenging to determine due to limited statistics and its incorporation with mucosal forms. While most cases have a favorable prognosis, challenges arise in patients presenting with locally advanced or metastatic forms, mainly appearing in immunocompromised patients, solid organ transplantation recipients, or those facing social difficulties. Traditionally, chemotherapy and targeted therapy were the mainstays for advanced cases, but recent approvals of immunotherapeutic agents like cemiplimab and pembrolizumab have revolutionized treatment options. These guidelines, developed by the Italian Association of Medical Oncologists (AIOM) using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach, aim to guide clinicians in diagnosing, treating, and monitoring patients with CSCC, covering key aspects from primitive tumors to advanced stages, selected by a panel of experts selected by AIOM and other national scientific societies. The incorporation of these guidelines into clinical practice is expected to enhance patient care and address the evolving landscape of CSCC management.  \nKey words: cutaneous squamous cell carcinoma, CSCC, anti-PD-1, cemiplimab, skin cancer, keratinocyte carcinoma, GRADE, guidelines  \nINTRODUCTION  \nCutaneous squamous cell carcinoma (CSCC) accounts for w20%-25% of skin tumors. However, the precise incidence data for this neoplasm are not well-defined due to limited statistics and its frequent inclusion with mucosal forms.1 In Italy, the 2015 Italian Cancer Registry Association (AIRTUM) report estimated that w19 000 new cases of CSCC will be diagnosed in 2018, with higher incidence in males,  \n*Correspondence to: Prof. Francesco Spagnolo, Oncologia Medica 2, IRCCSOspedale Policlinico San Martino, Largo R. Benzi 10, 16132, Genova, Italy. Tel:þ390105558","cbCaiabKPdWNOIun","https://ap.wps.com/l/cbCaiabKPdWNOIun","pdf",466037,16,"English","# Introduction\n# Epidemiology and clinical burden\n# Treatment landscape and rationale for guidelines\n# Evidence evaluation and recommendations framework (GRADE)\n# Coverage of diagnosis, treatment, and monitoring","[{\"question\":\"What is cutaneous squamous cell carcinoma (CSCC) and how common is it?\",\"answer\":\"CSCC accounts for about 20%–25% of all skin tumors. Precise incidence is often hard to determine due to limited statistics and its frequent inclusion with mucosal forms.\"},{\"question\":\"Who is at higher risk of locally advanced or metastatic CSCC?\",\"answer\":\"Patients who are immunocompromised, solid organ transplant recipients, or those facing social difficulties are more likely to develop locally advanced or metastatic disease.\"},{\"question\":\"What approach do the guidelines use to evaluate evidence and make recommendations?\",\"answer\":\"The Italian Association of Medical Oncologists (AIOM) developed the guidelines using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach.\"}]","Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma - a GRADE approach for evidence evaluation and recommendations | PDF",1790029149]